ANTITOXIN
Private Company
Total funding raised: $18.2M
Overview
Antitoxin GmbH is a well-established, privately-held German IVD manufacturer with a 58-year history as a reliable supplier in the niche field of blood typing reagents. The company operates as an expert OEM and bulk producer for global IVD leaders and local distributors, leveraging deep experience in transfusion medicine to develop and supply a comprehensive range of antisera, enzymes, and enhancers. Its core business is complemented by proprietary R&D in erythrocyte stabilization (Imu Solutions) and a novel point-of-care test card designed to prevent transfusion errors. As a revenue-generating entity, Antitoxin occupies a specialized position in the diagnostics supply chain, serving a critical but stable market with high-quality, certified products.
Technology Platform
Expertise in formulation and validation of immunological IVD reagents, particularly blood typing antisera. Proprietary R&D in erythrocyte stabilization (Imu Solutions) and development of wet chemistry point-of-care test cards for bedside ABO verification.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Antitoxin competes in a specialized niche against other reagent specialists and the in-house production capabilities of large, integrated IVD corporations like Ortho Clinical Diagnostics (now part of QuidelOrtho), Bio-Rad, and Grifols. Its competitive edge is its deep expertise, long-standing reputation, comprehensive rare sera portfolio, and flexible OEM manufacturing model, rather than scale or breadth of product line.